ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "neutropenia"

  • Abstract Number: 1940 • 2018 ACR/ARHP Annual Meeting

    Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety

    Jeffrey R. Curtis1, Gregory St. John2, Michael Pannucci2, Yong Lin3, José A. Maldonado-Cocco4, Tom W.J. Huizinga5, Marina Stanislav6 and Paul Emery7, 1University of Alabama, Birmingham, AL, 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Sanofi Genzyme, Bridgewater, NJ, 4Universidad de Buenos Aires, Buenos Aires, Argentina, 5Leiden University Medical Center, Leiden, Netherlands, 6Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russian Federation, 7University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

    Background/Purpose: In sarilumab randomized controlled trials (RCTs), dose delay and/or reduction was recommended for management of patients who developed neutropenia Grade (G) 3 (ANC ≥500…
  • Abstract Number: 567 • 2015 ACR/ARHP Annual Meeting

    Rituximab Associated Late Onset Neutropenia – a Rheumatology Case Series and Review of the Literature

    William Monaco1, William F.C. Rigby2 and Jonathan Jones3, 1Internal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH

    Background/Purpose: Rituximab (RTX) has been associated with late onset neutropenia (LON), defined as an absolute neutrophil count (ANC) < 1.5 x 109/L at least 4 weeks…
  • Abstract Number: 1530 • 2015 ACR/ARHP Annual Meeting

    Neutrophil Function and Survival Unaffected in Healthy Subjects Following Single Administration of Tocilizumab

    Laurence Lok1, Jatinder Juss1, Neda Farahi1, Chrystalla Loutsios1, Chandra Solanki2, Adrien Michael Peters3, Sophie Dimonaco4, Francis Donaldson4, Benjamin Porter-Brown4 and Edwin Chilvers1, 1Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 2Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge, United Kingdom, 3Division of Clinical and Laboratory Investigation, Brighton and Sussex Medical School, Brighton, United Kingdom, 4Roche Products Ltd., Welwyn Garden City, United Kingdom

    Background/Purpose: Decreases in circulating neutrophil counts have been observed in adults with rheumatoid arthritis (RA) and children with systemic or polyarticular juvenile idiopathic arthritis treated…
  • Abstract Number: 2903 • 2015 ACR/ARHP Annual Meeting

    Late-Onset Neutropenia Following Rituximab Treatment in Patients with Systemic Lupus Erythematosus

    Ioannis Parodis, Frida Söder, Ronald F. van Vollenhoven, Elisabet Svenungsson and Iva Gunnarsson, Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: The incidence and clinical consequences of rituximab-mediated late-onset neutropenia (LON) have been studied in various diseases, but data from Systemic Lupus Erythematosus (SLE) are…
  • Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting

    Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis

    V. Strand1, A. Dikranian2, J. Beal3, K. Kwok3, S. Krishnaswami4, S. Wood4 and C. Nduaka4, 1Biopharmaceutical Consultant, Portola Valley, CA, 2San Diego Arthritis Medical Clinic, San Diego, CA, 3Pfizer Inc, New York, NY, 4Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…
  • Abstract Number: 680 • 2014 ACR/ARHP Annual Meeting

    Influence of Antimalarial doesn´t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus

    Eugenia Enriquez Merayo1, Maria Galindo Izquierdo2, Esther Rodriguez-Almaraz3, Maria Martin Lopez2, Otto Martin Olivas Vergara4, Patricia E. Carreira5 and Isabel Mateo6, 1RHEUMATOLOGY, 12 DE OCTUBRE, MADRID, Spain, 2RHEUMATOLOGY, HOSPITAL 12 DE OCTUBRE, MADRID, Spain, 3Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, 4HOSPITAL 12 DE OCTUBRE, MADRID, Spain, 5Rheumatology Department. Hospital Universitario 12 de Octubre, Madrid, Spain, 6Servicio De Reumatología, Hospital 12 De Octubre,, Madrid, Spain

    Background/Purpose: To analyze the effect of antimalarials (AM) as preventive factor for the development of severe cytopenias and in their outcome after treatment in a…
  • Abstract Number: 273 • 2013 ACR/ARHP Annual Meeting

    Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis

    Fabrizio De Benedetti1, Hermine Brunner2, Eileen M. Baildam3, Ruben Burgos-Vargas3, Gerd Horneff3, Hans-Iko Huppertz3, Kirsten Minden4, Barry L. Myones2, Karen Onel5, Jianmei Wang6, Kamal N. Bharucha7, Daniel J. Lovell2, Alberto Martini8 and Nicolino Ruperto3, 1IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, 2PRCSG, Cincinnati, OH, 3PRINTO, Genoa, Italy, 4Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, 5Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 6Roche Products Ltd., Welwyn Garden City, United Kingdom, 7Genentech, South San Francisco, CA, 8Pediatria II, Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: In the phase 3 TENDER trial of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA), decreases in neutrophil count were commonly observed.…
  • Abstract Number: 1699 • 2012 ACR/ARHP Annual Meeting

    Neutropenia After Rituximab in Rheumatoid Arthritis and Other Autoimmune Diseases Is a Rare Events : Date From the Autoimmunity and Rituximab Registry

    Jean Hugues Salmon1, Patrice Cacoub2, Bernard G. Combe3, Jean Sibilia4, Beatrice Pallot Prades5, Olivier Fain6, Alain G. Cantagrel7, Maxime Dougados8, Olivier Meyer9, Philippe Carli10, Edouard Pertuiset11, Isabelle Pane12, Philippe Ravaud13, Xavier Mariette14 and Jacques-Eric Gottenberg15, 1Rheumatology, Reims, France, 2Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 3Rhumatologie, Hopital Lapeyronie, Montpellier, France, 4Rheumatology, CHU Hautepierre, Strasbourg, France, 5Rheumatology department, Saint Etienne university hospital, Saint Etienne, France, 6Internal Medicine, Jean Verdier Hospital, Bondy, France, 7Rheumatology, Place du Docteur Baylac, Toulouse, France, 8Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 9Rheumatology, Hopital Bichat, Paris, France, 10HIA sainte Anne, Toulon, France, 11Rheumatology, Ch Rene Dubos, Pontoise, France, 12Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, 13Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 14Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, 15Rheumatology, Strasbourg University Hospital, Strasbourg, France

    Background/Purpose: Limited data are available regarding the proportion and severity of late onset neutropenia after RTX in large and unselected populations of patients with various…
  • Abstract Number: 1302 • 2012 ACR/ARHP Annual Meeting

    Early Neutropenia Is Associated with Clinical Response in Patients Receiving Tocilizumab in Rheumatoid Arthritis

    Marie Kostine1, Thomas Barnetche2, Elodie Ardouin3, Marlene Joly4, Emilie Rabois5, Baptiste Glace Sr.6, Delphine Nigon7, Thierry Schaeverbeke8 and Christophe Richez9, 1Rheumatology, CHU Pellegrin, Bordeaux, France, 2Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, 3Rheumatology, Limoges University Hospital, Limoges, France, 4Rheumatology, Montpellier University Hospital, Montpellier, France, 5Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 6Rheumatology, Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, 7CHU Purpan, Toulouse, France, 8Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, 9Hôpital Pellegrin and Université Victor Segalen Bordeaux, France

    Background/Purpose: A reduction in peripheral blood neutrophils count is usually observed with the anti-interleukin (IL) 6 receptor antibody tocilizumab. This often appears few days after…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology